SFGate - Roche is reportedly willing to pay Genentech $95 a share, up from the $93 that the Swiss drugmaker offered on Friday, to acquire full control of the South San Francisco biotech pioneer in what would be a $46.7 billion deal.
SFGate - Roche is reportedly willing to pay Genentech $95 a share, up from the $93 that the Swiss drugmaker offered on Friday, to acquire full control of the South San Francisco biotech pioneer in what would be a $46.7 billion deal.
